De Duve Institute, Université Catholique de Louvain, Avenue Hippocrate 75, Box B1.74.05, 1200, Brussels, Belgium.
Cell Mol Life Sci. 2021 Apr;78(8):3867-3881. doi: 10.1007/s00018-020-03753-y. Epub 2021 Jan 15.
PDGFRA and PDGFRB are classical proto-oncogenes that encode receptor tyrosine kinases responding to platelet-derived growth factor (PDGF). PDGFRA mutations are found in gastrointestinal stromal tumors (GISTs), inflammatory fibroid polyps and gliomas, and PDGFRB mutations drive myofibroma development. In addition, chromosomal rearrangement of either gene causes myeloid neoplasms associated with hypereosinophilia. Recently, mutations in PDGFRB were linked to several noncancerous diseases. Germline heterozygous variants that reduce receptor activity have been identified in primary familial brain calcification, whereas gain-of-function mutants are present in patients with fusiform aneurysms, Kosaki overgrowth syndrome or Penttinen premature aging syndrome. Functional analysis of these variants has led to the preclinical validation of tyrosine kinase inhibitors targeting PDGF receptors, such as imatinib, as a treatment for some of these conditions. This review summarizes the rapidly expanding knowledge in this field.
PDGFRA 和 PDGFRB 是经典的原癌基因,编码对血小板衍生生长因子(PDGF)有反应的受体酪氨酸激酶。PDGFRA 突变存在于胃肠道间质瘤(GISTs)、炎症性纤维瘤息肉和神经胶质瘤中,PDGFRB 突变驱动肌纤维瘤的发展。此外,这两个基因的染色体重排导致伴有嗜酸性粒细胞增多的髓系肿瘤。最近,PDGFRB 的突变与几种非癌症疾病有关。在原发性家族性脑钙化中发现了降低受体活性的种系杂合变体,而在梭形动脉瘤、Kosaki 过度生长综合征或 Penttinen 早衰综合征患者中存在功能获得性突变。对这些变体的功能分析导致了针对 PDGF 受体的酪氨酸激酶抑制剂(如伊马替尼)的临床前验证,作为这些疾病的一些治疗方法。这篇综述总结了这一领域快速扩展的知识。